Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second-line anti-retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir-boosted lopinavir (Aluvia tablets) following initiation with 24 weeks of combination therapy in second-line anti-retroviral therapy in Africa

Next Previous
X
Search
Trial Profile

Second-line anti-retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir-boosted lopinavir (Aluvia tablets) following initiation with 24 weeks of combination therapy in second-line anti-retroviral therapy in Africa

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SARA

    • Most Recent Events

    • 19 Jul 2012 Results published in Antiviral Therapy.
    • 23 Jul 2010 Efficacy results have been presented at the 18th International AIDS Conference.
    • 24 Jun 2010 Primary endpoint 'CD4+-cell-count' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top